title: Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
abstract: The favourable experience with the combination regimen of vinorelbine, ifosfamide and cisplatin (NIP) in patients with metastatic non-small cell lung cancer (NSCLC) has led to a protocol assessing this regimen as an induction treatment in patients with stage III unresectable NSCLC, followed by thoracic radiotherapy with concurrent daily cisplatin as a radiosensitizer. Two cycles of NIP were administered 21 days apart; each cycle comprised i.v. vinorelbine 25 mg/m2 on days 1 and 8, i.v. ifosfamide 3 g/m2 on day 1 with MESNA as uroprotection, and i.v. cisplatin 50 mg/m2 on day 1. Radical thoracic radiotherapy commenced on day 43 to a total dose of 64 Gy and i.v. cisplatin 6 mg/m2 was given concurrently prior to each fraction of radiation as a sensitiser. Two more cycles of NIP were given to patients who responded favourably to the induction treatment about 2 weeks after completion of radiation. Between July 1995 and July 1997, 44 patients were treated with this protocol. This treatment schedule was generally well tolerated. Grade 3-4 neutropenia occurred in 50% of the patients and neutropenic sepsis was seen in 8. Grade 3-4 oesophagitis was uncommon. Most of the patients were able to complete the induction and concurrent chemoradiotherapy phase. Major response occurred in 75% of the patients with 2 (4.5%) complete responses (CR). A total of 6 patients achieved CR after chemoradiotherapy. At a median follow-up of 35 months, the median overall survival for all patients was 15 months with a 3-year survival rate of 24%. The median overall survival for stage IIIA patients was 19 months with a 3-year survival rate of 39% in contrast to 13 months' median overall survival and only 15% 3-year survival rate for stage IIIB. The NIP regimen results in a high response rate in NSCLC and this treatment programme seems to benefit selected patients with stage III disease.
authors.affiliation: Department of Medical Oncology, National Cancer Centre, Singapore, Singapore.
authors.forename: E H
authors.initials: EH
authors.lastname: Tan
authors.forename: J
authors.initials: J
authors.lastname: Wee
authors.forename: P T
authors.initials: PT
authors.lastname: Ang
authors.forename: K W
authors.initials: KW
authors.lastname: Fong
authors.forename: S S
authors.initials: SS
authors.lastname: Leong
authors.forename: K S
authors.initials: KS
authors.lastname: Khoo
authors.forename: T
authors.initials: T
authors.lastname: Tan
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Eng
authors.forename: A
authors.initials: A
authors.lastname: Hsu
authors.forename: Y K
authors.initials: YK
authors.lastname: Tan
authors.forename: E J
authors.initials: EJ
authors.lastname: Chua
authors.forename: Y Y
authors.initials: YY
authors.lastname: Ong
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D011838:Radiation-Sensitizing Agents; D014747:Vinblastine; D002945:Cisplatin; D007069:Ifosfamide